Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 2;10:2. doi: 10.1038/s41523-023-00605-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — To qualify breast cancer-related antibodies, the BC03 TMA, representing 16 breast tumors in duplicate was used. a–c CyCIF was performed using the qualified CyCIF antibody against a single antibody commonly used in clinical practice as a reference for ER (a), PR (b), and HER2 (c). The left graph depicts a single-cell dot-plot between the clinical clone on the x axis and the validated CyCIF antibody on the y axis. Each dot represents single-cell fluorescent intensity values from the two antibodies. Dashed lines indicate the gating cutoffs. The middle graph shows the corresponding mean log intensity of the core-to-core analysis of the clinical and CyCIF antibodies. The single-cell data were collected for individual TMA cores, with a binary gate applied to obtain the positive signal of each core (range from 0–1). The X- & Y axis represent the positive score calculated from either clinical or CyCIF antibodies, respectively. The right graph shows positivity scores (number of positive cells over total cells) for the clinical and CyCIF antibodies by TMA case. d, e Cross-assay comparison of the clinical and CyCIF antibodies analyzed by CyCIF compared to the clinical antibody analyzed by IHC using Aperio software for ER (d) and HER2 (e). Left, dot-plot representation of two different scores obtained from CyCIF and from IHC-Aperio. CyCIF of clinical (green dots) and CyCIF antibodies (blue dots) were used on the same section, while IHC was performed on a different section from the same TMA block. Each dot represents a single core from BC03 TMA. CyCIF scores are plotted on y axis as positive ratio of immunofluorescence, IHC scores on x axis are plotted as the percent of positive cells. Right graph, quantitative assessment of ER and HER2 IHC versus CyCIF staining. IHC scores by Aperio were used to stratify (0–24, 25–49, 50–74, 75–100) different TMA cores/cases, and the mean intensities of CyCIF antibody staining from each TMA core are shown using boxplot analysis. CyCIF antibodies: ER (CST 74244 S) and HER2 (ab225510).